ES2188730T3 - Producto que contiene rapamicina o derivados seleccionados y nmda- o ampa-antagonista utilizado para tratamiento de epilepsia o enfermedad de huntington y utilizacion de rapamicina o derivados seleccionados para prepar. de medicamento para trat. de epilepsia o enferm. huntigton. - Google Patents

Producto que contiene rapamicina o derivados seleccionados y nmda- o ampa-antagonista utilizado para tratamiento de epilepsia o enfermedad de huntington y utilizacion de rapamicina o derivados seleccionados para prepar. de medicamento para trat. de epilepsia o enferm. huntigton.

Info

Publication number
ES2188730T3
ES2188730T3 ES96308786T ES96308786T ES2188730T3 ES 2188730 T3 ES2188730 T3 ES 2188730T3 ES 96308786 T ES96308786 T ES 96308786T ES 96308786 T ES96308786 T ES 96308786T ES 2188730 T3 ES2188730 T3 ES 2188730T3
Authority
ES
Spain
Prior art keywords
rapamycin
epilepsy
selected derivatives
huntigton
trat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96308786T
Other languages
English (en)
Inventor
Stephen Shi-Hsun Lin
Katherine Lu Molnar-Kimber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Application granted granted Critical
Publication of ES2188730T3 publication Critical patent/ES2188730T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ESTA INVENCION PROPORCIONA UN METODO PARA USAR RAPAMICINA, RAPAMICINA 1,3-CON UNION DE DIEL QUE ADUCE CON FENILTRIAZOLINEDIONA, RAPAMICINA 42-ESTER CON ACIDO BENZENESULFONICO 4-[[4-DIMETILAMINO)FENIL]AZO], RAPAMICINA 1,3-CON UNION DE DIEL QUE ADUCE CON METILTRIAZOLINEDIONA, O RAPAMICINA-O-BENZIL-27OXIMA COMO AGENTE NEUROPROTECTOR.
ES96308786T 1995-12-07 1996-12-04 Producto que contiene rapamicina o derivados seleccionados y nmda- o ampa-antagonista utilizado para tratamiento de epilepsia o enfermedad de huntington y utilizacion de rapamicina o derivados seleccionados para prepar. de medicamento para trat. de epilepsia o enferm. huntigton. Expired - Lifetime ES2188730T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US833795P 1995-12-07 1995-12-07

Publications (1)

Publication Number Publication Date
ES2188730T3 true ES2188730T3 (es) 2003-07-01

Family

ID=21731060

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96308786T Expired - Lifetime ES2188730T3 (es) 1995-12-07 1996-12-04 Producto que contiene rapamicina o derivados seleccionados y nmda- o ampa-antagonista utilizado para tratamiento de epilepsia o enfermedad de huntington y utilizacion de rapamicina o derivados seleccionados para prepar. de medicamento para trat. de epilepsia o enferm. huntigton.

Country Status (23)

Country Link
EP (1) EP0778023B1 (es)
JP (1) JPH09183727A (es)
KR (1) KR970032856A (es)
CN (1) CN1112925C (es)
AR (1) AR008747A1 (es)
AT (1) ATE234095T1 (es)
AU (1) AU700653B2 (es)
BR (1) BR9605895A (es)
CA (1) CA2192298A1 (es)
CZ (2) CZ6498A3 (es)
DE (1) DE69626610T2 (es)
DK (1) DK0778023T3 (es)
ES (1) ES2188730T3 (es)
HU (1) HUP9603370A3 (es)
IL (1) IL119778A (es)
MX (1) MX9606131A (es)
NO (1) NO309966B1 (es)
NZ (1) NZ299888A (es)
PT (1) PT778023E (es)
SI (1) SI0778023T1 (es)
SK (1) SK154796A3 (es)
TW (1) TW427904B (es)
ZA (1) ZA9610245B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1002535A1 (en) 1998-10-28 2000-05-24 Hrissanthi Ikonomidou New use of glutamate antagonists for the treatment of cancer
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
US6417189B1 (en) * 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
FR2806626B1 (fr) * 2000-03-22 2003-11-28 Centre Nat Rech Scient Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aigues
AU2001255406A1 (en) * 2000-04-17 2001-10-30 Gpi Nil Holdings, Inc. Cyclic diaza compounds for treating neurodegenerative disorders
GB0117645D0 (en) * 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
UA78529C2 (en) 2001-10-10 2007-04-10 Wyeth Corp Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain
US20030176455A1 (en) * 2002-03-13 2003-09-18 Wyeth Method of inhibiting cell death
PL1611144T3 (pl) 2003-04-09 2011-03-31 Wyeth Llc Pochodne kwasu 2-(8,9-diokso-2,6-diazabicyklo(5.2.0)non-1(7)-en-2-ylo)alkilofosfonowego i ich zastosowanie jako antagonistów receptora N-metylo-D-asparaginianu (NMDA)
AU2004229567A1 (en) * 2003-04-09 2004-10-28 Wyeth Pharmaceutical compositions for intranasal administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1 (7)-en-2-yl)alkyl] phosphonic acid and derivatives and methods of use thereof
US20070155771A1 (en) * 2003-04-11 2007-07-05 David Rubinsztein Methods and means for treating protein conformational disorders
US7485706B2 (en) * 2003-07-30 2009-02-03 The Board Of Trustees Of The Leland Stanford Junior University Neurodegenerative protein aggregation inhibition methods and compounds
TW200514775A (en) 2003-10-22 2005-05-01 Wyeth Corp Methods for the preparation of {2-[(8,9)-dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl]ethyl} phosphonic acid and esters thereof
ES2380779T3 (es) * 2004-12-20 2012-05-18 Wyeth Llc Análogos de rapamicina y usos de los mismos en el tratamiento de trastornos neurológicos, proliferativos e inflamatorios
CN101084226A (zh) 2004-12-20 2007-12-05 惠氏公司 雷帕霉素衍生物及其治疗神经紊乱的用途
JP4857071B2 (ja) * 2006-10-12 2012-01-18 潤平 笹部 筋萎縮性側策硬化症（ａｌｓ）の検出方法
EP2065038A1 (en) 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
CN104997774A (zh) * 2009-04-10 2015-10-28 齐海燕 新的抗衰老试剂及其鉴别方法
EP2263665A1 (en) * 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
EP2456437A4 (en) * 2009-07-24 2013-01-09 Inst Nat Rech Scient COMBINATION THERAPY FOR TAUOPATHIES
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US9121859B2 (en) 2012-12-04 2015-09-01 Siemens Healthcare Diagnostics Inc. Compounds and methods for determination of FKBP-binding immunosuppressant drugs
AU2014276856B2 (en) 2013-06-05 2018-11-15 Pharnext Stable oral solutions for combined API
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease
KR20200088856A (ko) * 2017-11-15 2020-07-23 벤더르빌트 유니버시티 리소좀 기능의 개선 및 퇴행성 신경 질환의 치료를 위한 방법 및 조성물
CN114366738A (zh) * 2021-12-20 2022-04-19 中国人民解放军军事科学院军事医学研究院 雷帕霉素在促进神经干细胞扩增中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
JPH04230389A (ja) * 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
IL101353A0 (en) * 1991-04-03 1992-11-15 American Home Prod Pharmaceutical compositions for treating diabetes
DE4118740A1 (de) * 1991-06-05 1992-12-10 Schering Ag Neue kombinationspraeparate zur behandlung des morbus parkinson
ZA924953B (en) * 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5260299A (en) * 1992-03-05 1993-11-09 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-Carboalkoxy)Sulfamates Useful as Immunosuppressive Agents
IL111003A0 (en) * 1993-09-30 1994-11-28 American Home Prod Multi-component oral rapamycin formulation

Also Published As

Publication number Publication date
CZ6498A3 (cs) 1998-06-17
DE69626610T2 (de) 2003-10-02
AU7417896A (en) 1997-06-12
NO309966B1 (no) 2001-04-30
NO965238D0 (no) 1996-12-06
HU9603370D0 (en) 1997-01-28
EP0778023B1 (en) 2003-03-12
EP0778023A1 (en) 1997-06-11
IL119778A0 (en) 1997-03-18
CZ354496A3 (cs) 1998-03-18
PT778023E (pt) 2003-06-30
BR9605895A (pt) 1998-08-18
ATE234095T1 (de) 2003-03-15
MX9606131A (es) 1997-08-30
HUP9603370A2 (en) 1997-05-28
ZA9610245B (en) 1998-06-05
IL119778A (en) 1999-07-14
NZ299888A (en) 2001-02-23
DE69626610D1 (de) 2003-04-17
TW427904B (en) 2001-04-01
AU700653B2 (en) 1999-01-14
SK154796A3 (en) 1997-09-10
HUP9603370A3 (en) 1998-12-28
KR970032856A (ko) 1997-07-22
SI0778023T1 (en) 2003-08-31
CN1159915A (zh) 1997-09-24
CN1112925C (zh) 2003-07-02
CA2192298A1 (en) 1997-06-08
NO965238L (no) 1997-06-09
JPH09183727A (ja) 1997-07-15
AR008747A1 (es) 2000-02-23
DK0778023T3 (da) 2003-06-30

Similar Documents

Publication Publication Date Title
ES2188730T3 (es) Producto que contiene rapamicina o derivados seleccionados y nmda- o ampa-antagonista utilizado para tratamiento de epilepsia o enfermedad de huntington y utilizacion de rapamicina o derivados seleccionados para prepar. de medicamento para trat. de epilepsia o enferm. huntigton.
BR0109446A (pt) Medicamento para a aplicação intracorpórea, uso de um xanteno halogenado, composição farmacêutica, e, método de tratamento
PT730864E (pt) Medicamento para tratar doencas inflamatorias cardiacas
BR9608405A (pt) Composto composi-Æo farmaceutica e processo para tratar um paciente que sofre de um distÚrbio fisiolÄgico
BR9808938A (pt) Composto, composição farmacêutica, uso de um composto, processos para o tratamento de um distúrbio ou doença de um corpo de animal vivo e para a preparação de um composto, e, uso de bloqueadores de canal de cloreto
MXPA03003354A (es) Dispositivos medicos revestidos para el tratamiento de una enfermedad vascular.
GEP20022786B (en) Purine Inhibitors of Cyclin Dependent Kinase 2 and 1kB-a
BRPI0111116B8 (pt) imitadores de trombopoietina
ES2141393T3 (es) Uso de oligonucleotidos sustituidos en posicion 2' para regulacion supresora de la expresion genica.
FI971974A (fi) Tienopyridiini- tai tienopyrimidiinijohdannaiset ja niiden käyttö
ES2190541T3 (es) Procedimiento para la utilizacion de oligonucleotidos con dinucleosidos cpg modificados.
ATE205086T1 (de) Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit
DE69833375D1 (de) Implantate zur gesteuerten freisetzung von pharmazeutischen wirkstoffen und verfahren zur herstellung
ES2187566T3 (es) Formulaciones farmaceuticas mejoradas que contienen ibuprofeno y codeina.
DE69621132T2 (de) Verwendung von hyaluronsäure und eines nsaid zur herstellung eines arzneimittels zur behandlung von krankheiten der mucosa
DE69801660D1 (de) Lokale behandlung von psoriasis unter verwendung neutralisierender antikörper gegen il-8
WO1997003188A3 (de) Verwendung von mp52 oder mp121 zur behandlung und prävention von erkrankungen des nervensystems
DE69814394D1 (de) Verwendung von levobupivacain
DE60112777D1 (de) Beschichtete medizinische geräte und verfahren zur sterilisation
BRPI0411503A (pt) composto, composição farmacêutica, uso de um composto, método de tratar um ser humano que sofre de uma doença hiperproliferativa tal como cáncer, e, processo para a preparação de um composto
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
AU3611299A (en) Use of metalloprotinease inhibitors for inducing and/or stimulating growth of hair or hairs and/or for slowing down their loss
ES2180774T3 (es) La utilizacion de triacetato de glicerilo para el tratamiento de onicomicosis.
FR2801792B1 (fr) Un nouveau medicament, le dihydromikanolide, son obtention par extraction de la plante mikania micrantha et son utilisation comme agent anti-proliferatif
EP0744176A3 (en) Methods for inhibiting bone loss